SYNAVANT created from IMS Health spin-off
SYNAVANT Inc, claiming to be the first pharmaceutical relationshipmanagement solutions provider, has been created through IMS Health's spin-off of its Strategic Technologies and Clark-O'Neill divisions.
SYNAVANT says its products include Pharbase, a physician database, and "advanced interactive marketing services tailored to the health care industry." The firm "is offering what our clients requested," said chairman and chief executive Wayne Yetter (who, prior to joining IMS in 1999, was president and CEO of Novartis Pharmaceuticals Corp). He added that, "through our solutions, we are able to help our clients bring their products to market faster and more effectively." For more details, visit: www.synavant.com.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze